<DOC>
	<DOC>NCT00837824</DOC>
	<brief_summary>This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.</brief_summary>
	<brief_title>Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>provided written informed consent prior to any studyrelated procedures being performed. be ≥16 years old. have a current diagnosis of Fabry disease (defined as abnormal αgalactosidase (α GAL) enzyme levels or Fabry genotype). have one of the following clinical conditions present at enrollment: serum creatinine level greater than 3.0 mg/dL (an average of two values at least one week apart), or be currently on dialysis, or be status post kidney transplant by greater than 3 months. have the ability to comply with the requirements of the protocol have a negative pregnancy test, if a female patient of childbearing potential. In addition, all female patients of childbearing potential must use a medically accepted method of contraception throughout the study. if they did not meet the specific inclusion criteria. if they had participated in a study employing an investigational drug within 30 days of the start of their participation in this trial. had previously received enzyme replacement therapy (ERT) for their Fabry disease. had diabetic nephropathy. were pregnant or lactating. were unwilling to comply with the requirements of the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fabry Disease patients with Severe Renal Disease</keyword>
</DOC>